Differential DNA methylation analysis of SUMF2, ADAMTS5, and PXDN provides novel insights into colorectal cancer prognosis prediction in Taiwan

doi:10.3748/wjg.v28.i8.825

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 28, Issue 8

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7378)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-4) series.

Item

Count

PDF

336

WORD

105

HTML

3347

Figures (1-5)

925

Tables (1-4)

432

Sum=5145

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

364

Download

600

Sum=964

Publishing Process of This Article

Item

Count

Browse

448

Download

821

Sum=1269

Feb 28, 2022 (publication date) through Mar 7, 2025

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastroenterol. Feb 28, 2022; 28(8): 825-839
Published online Feb 28, 2022. doi: 10.3748/wjg.v28.i8.825

Table 4 Multivariate 5-year progression and survival analysis of SUMF2 and ADAMTS5 gene

	RFS		PFS		OS
	cHR (95%CI)	aHR (95%CI)¹	cHR (95%CI)	aHR (95%CI)¹	cHR (95%CI)	aHR (95%CI)²
SUMF2 in tumor tissue
CpG_3+CpG_7
Hypomethylation	1.00 (Reference)	1.00 (Reference)	1.00 (Reference)	1.00 (Reference)	1.00 (Reference)	1.00 (Reference)
Hypermethylation	2.37 (0.86-6.55)	1.64 (0.55-4.89)	2.24 (1.03-4.85)^a	2.05 (0.91-4.62)	2.56 (1.08-6.04)^a	3.53 (1.35-9.26)^a
ADAMTS5 in normal tissue
CpG_2
Hypomethylation	1.00 (Reference)	1.00 (Reference)	1.00 (Reference)	1.00 (Reference)	1.00 (Reference)	1.00 (Reference)
Hypermethylation	0.15 (0.03-0.71)^a	0.17 (0.03-0.95)^a	0.57 (0.24-1.37)	0.54 (0.21-1.41)	0.82 (0.31-2.16)	0.94 (0.31-2.85)
CpG_13
Hypomethylation	1.00 (Reference)	1.00 (Reference)	1.00 (Reference)	1.00 (Reference)	1.00 (Reference)	1.00 (Reference)
Hypermethylation	0.20 (0.04-0.97)^a	0.16 (0.03-0.85)^a	0.48 (0.19-1.19)	0.45 (0.17-1.18)	0.50 (0.19-1.30)	0.72 (0.24-2.15)

¹Adjusted for sex, age, and stage.

²Adjusted for sex, age, stage, and lymph node counts.

^aP < 0.05. RFS: Recurrence-free survival; PFS: Progression-free survival; OS: Overall survival; cHR: Crude hazard ratio; aHR: Adjusted hazard ratio; CI: Confidence interval; SUMF2: Sulfatase modifying factor 2; ADAMTS5: ADAM metallopeptidase with thrombospondin type 1 motif 5.

Citation: Su JQ, Lai PY, Hu PH, Hu JM, Chang PK, Chen CY, Wu JJ, Lin YJ, Sun CA, Yang T, Hsu CH, Lin HC, Chou YC. Differential DNA methylation analysis of SUMF2, ADAMTS5, and PXDN provides novel insights into colorectal cancer prognosis prediction in Taiwan. World J Gastroenterol 2022; 28(8): 825-839
URL: https://www.wjgnet.com/1007-9327/full/v28/i8/825.htm
DOI: https://dx.doi.org/10.3748/wjg.v28.i8.825